New drug lebrikizumab put to the test in healthy chinese participants
NCT ID NCT06243198
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested the safety and tolerability of a single dose of lebrikizumab in 24 healthy Chinese adults. Half received the drug and half received a placebo, with researchers monitoring side effects and how the drug enters and leaves the body. The study is complete and provides basic safety data for this drug in a Chinese population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lebrikizumab
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test